Annexon (NASDAQ: ANNX) Issues Press Release Outlining 2025 Outlook

Brisbane, Calif. – On January 13, 2025, Annexon, Inc. (NASDAQ: ANNX) disclosed essential information in a press release titled “Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year.” This communication highlighted the company’s strategic plans and significant developments for its lead programs: ANX005 in Guillain-Barré syndrome (GBS), ANX007 in geographic atrophy (GA), and the oral small molecule ANX1502 designed for various diseases.

According to the press release, Annexon is diligently preparing for major milestones in 2025, outlining progress for each of its flagship programs. The ANX005 program targets Guillain-Barré syndrome, aiming to enhance muscle strength and functional recovery rapidly, potentially revolutionizing the standard of care. Annexon anticipates submitting a Biologics License Application (BLA) for ANX005 in the first half of 2025.

Additionally, the program focusing on ANX007 for geographic atrophy revealed positive outcomes from its Phase 2 ARCHER study, showcasing remarkable vision preservation results. The ongoing registrational Phase 3 ARCHER II trial is on track, with an estimated completion for enrollment in the second half of 2025 and data awaited in the latter half of 2026.

Moreover, the company’s ANX1502 program, an innovative oral C1s inhibitor, shows promise across autoimmune conditions. Annexon has completed crucial studies confirming the safety and pharmacokinetic profiles of this candidate. Future steps include evaluating the tablet formulation in a cold agglutinin disease study to inform further clinical development.

With high expectations and diligent efforts, Annexon’s leadership remains focused on delivering groundbreaking therapies to enhance the lives of patients battling complement-mediated neuroinflammatory diseases. The company’s commitment to pioneering science and potential groundbreaking treatments underscores its dedication to transforming the healthcare landscape.

This press release, including the Company’s 2025 outlook and key catalysts, provides a comprehensive overview of Annexon’s strategic roadmap for the year, signifying a crucial period of acceleration and advancement in its therapeutic programs.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Annexon’s 8K filing here.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.